Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 168

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 168
---
    $
    (86,481
    )
     
    $
    (69,134
    )
     
    $
    (17,347
    )

Research and Development Expenses

We track most external development costs by development program. We do not allocate internal costs, such as personnel-related expenses, stock-based compensation expense, facility, supplies and certain external consultant costs, to individual development programs.

107

The following table summarizes our research and development expenses by development program for the periods indicated (in thousands):

    Year Ended December 31,

    2024

    2023

    Change

    External research and development expenses by program

    TYRA-300ACH
     
    $
    7,718

    $
    5,268

    $
    2,450

    TYRA-300mUC

    14,319

    15,613

    (1,294
    )

    TYRA-430

    5,677

    4,987

    690

    TYRA-200

    4,969

    4,418

    551

    FGFR discovery

    8,321

    5,492

    2,829

    Other development programs

    2,537

    2,448

    89

    Unallocated research and development expenses

    Personnel costs

    30,423

    20,039

    10,384

    Facilities and other costs

    6,113

    4,253

    1,860

    Total research and development expenses
     
    $
    80,077

    $
    62,518

    $
    17,559

Research and development expenses were $80.1 million and $62.5 million for the years ended December 31, 2024 and 2023, respectively. The overall increase of $17.6 million was driven by:

•$7.3 million increase in clinical costs driven by progression of SURF301 and SURF201 clinical trials and start-up activities related to BEACH301, SURF302 and SURF431 study launches;

•$1.7 million decrease in preclinical costs due to a decrease in early drug discovery and toxicology costs as various programs moved into clinical development; 

•$0.3 million decrease in CMC costs for most programs in the clinical stage, except for TY